Brolucizumab in age-related macular degeneration, HAWK Study
3 October 2023
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
|
Neovascular age-related macular degeneration, aflibercept, anti-vascular endothelial growth factor therapy, brolucizumab, commercial formulation
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
